The PD-L2-related vaccine could serve as a complementary therapy and immune checkpoint inhibitor because competitive therapy could work along both lines by preventing the inhibition of PD-L2-specific T cells at the tumor site [41]. This evidence concerns the gene PDCD1LG2 and neoplasm.